e-learning
resources
ERJ
2018
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!
William W. Busse
Source:
Eur Respir J, 51 (5) 1800730; 10.1183/13993003.00730-2018
Journal Issue:
May
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
William W. Busse. Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!. Eur Respir J, 51 (5) 1800730; 10.1183/13993003.00730-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD?
Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights
Year: 2019
COPD treatment choices based on blood eosinophils: are we there yet?
Source: Breathe, 15 (4) 318; 10.1183/20734735.0254-2019
Year: 2019
Association between blood eosinophil count and control of allergic rhinitis: does it exist?
Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses
Year: 2019
Response to omalizumab treatment according to blood eosinophil count: Results of a French real-world study (STELLAIR)
Source: International Congress 2017 – Asthma: mechanisms and treatment
Year: 2017
Peripheral blood eosinophil counts in COPD patients and its relationship with prescription of inhaled corticosteroid in real world setting in Japan.
Source: International Congress 2017 – Airway disease and exacerbations
Year: 2017
Budesoinde/formoterol: does eosinophil count cause different outcomes?
Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts
Year: 2019
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial
Source: Eur Respir J, 58 (3) 2004522; 10.1183/13993003.04522-2020
Year: 2021
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study
Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017
Year: 2018
Mepolizumab does not alter blood basophil count in severe asthma
Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses
Year: 2019
ERJ October Podcast: blood eosinophil count as a biomarker in patients with airway disease
Source: Eur Respir J 2016; 48: E70
Year: 2016
Peripheral eosinophil count as a biomarker for the management of COPD: not there yet
Source: Eur Respir J, 50 (5) 1702165; 10.1183/13993003.02165-2017
Year: 2017
Could eosinophil / neutrophil ratio be used to determine treatment in COPD patients?
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018
The blood eosinophil count as a biomarker in COPD
Source: International Congress 2015 – Individualised risk reduction strategies for patients with COPD
Year: 2015
What can we learn from blood granulocyte patterns in patients with asthma?
Source: Eur Respir J 2016; 48: 976-978
Year: 2016
Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Lack of stability of blood eosinophil counts in patients with COPD.
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Long-term omalizumab treatment – do drug concentration levels count?
Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases
Year: 2020
One year monitoring of children with bronchial asthma and other allergic diseases treated with inhaled corticosteroids vs cromoglycates with serum ECP (S-ECP), FEV1, total IgE and blood eosinophil count - the influence of different therapy
Source: Eur Respir J 2002; 20: Suppl. 38, 432s
Year: 2002
Blood eosinophils fluctuation in asthmatics on Omalizumab-a mirror of disease outcomes improvement?
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Blood eosinophil count as a predictor of treatment response in adult patients with chronic cough
Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept